Abstract
Background/Objectives: Whether the magnitude and durability of prostate volume reduction after prostatic artery embolization (PAE) depend on baseline gland size is unclear. Methods: Retrospective single-operator study at two institutions (2015–2024): 164 of 177 consecutive men treated by PAE for benign prostatic hyperplasia with evaluable transrectal ultrasound volumetry were stratified as small (30–65 mL, n = 53), medium (>65–100 mL, n = 70) or large (>100 mL, n = 41); median follow-up was 12.8 months. The primary endpoint was relative volume reduction at nadir. Durability was analysed in a 6-month landmark cohort of early responders (n = 87), with regrowth to ≥80% of baseline as an interval-censored event (Turnbull estimator; Cox regression on midpoint-imputed event times). Results: Median reduction at nadir was 41.7%, 40.1% and 39.1% in small, medium and large glands (p = 0.39); 10 patients (6.1%) never fell below 80% of baseline. Regrowth occurred in 27 of 87 landmark patients; the probability of sustained reduction 24 months after the landmark was 0.76 (95% confidence interval [CI] 0.61–0.88). Baseline volume was not significantly associated with durability (hazard ratio 0.97 per 10 mL, 95% CI 0.86–1.10), consistently across sensitivity analyses and after adjustment for 5-alpha-reductase inhibitor pretreatment, which was more than twice as common in large glands; in an exploratory analysis, deeper reduction by the landmark was associated with longer durability. Conclusions: No association between baseline volume and the magnitude or durability of the volumetric response was detected, but the confidence intervals are wide and do not exclude a clinically relevant effect. The durability estimates are conditional on an early volumetric response and continued follow-up and should not be generalised to the entire treated population; residual confounding by medical therapy cannot be excluded, and the findings concern prostate volume, not clinical efficacy.